Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection

NCT03146520 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 634

Last updated 2018-04-18

No results posted yet for this study

Summary

Pivotal trials of SDC2 methylation biomarker test in stool DNA to estimate clinical sensitivity and specificity in detection of colorectal cancer.

Conditions

Interventions

DEVICE

EarlyTect Colon Cancer

SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit

Sponsors & Collaborators

  • Severance Hospital

    collaborator OTHER
  • Genomictree, Inc.

    lead INDUSTRY

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-13
Primary Completion
2018-03-18
Completion
2018-03-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03146520 on ClinicalTrials.gov